Press release
NICE recommends OXLUMO®▼ (lumasiran) in England as first therapy to treat underlying cause of ultra-rare condition primary hyperoxaluria type 1 (PH1)
March 20, 2023Business Services
MAIDENHEAD, UK, Monday 20th March 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a …
New data suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing
March 20, 2023Business Services
STEVENAGE, UK, March 20, 2023 – New data* presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in …
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
March 20, 2023Business Services
Basel, March 20, 2023 — Novartis today presented new data which underscore the transformational and sustained benefit of Zolgensma® (onasemnogene abeparvovec), …
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
March 20, 2023Business Services
Milan, Italy, March 20, 2023, 07:00 am CET – Newron Pharmaceuticals S.p.A.
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer
March 17, 2023Business Services
Addlestone UK, 17 March, 2023 –Astellas Pharma Ltd. (“Astellas”) today announced positive topline results from the Phase 3 EMBARK trial …
Newron to present at the 31st European Congress of Psychiatry
March 17, 2023Business Services
Milan, Italy, March 17, 2023, 7am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused …
iOnctura announces publication of pioneering research describing the unique biological features of roginolisib
March 16, 2023Business Services
Geneva, Switzerland and Amsterdam, The Netherlands, 16 March – iOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients …
PHARMANOVIA ENTERS INTO AN EXCLUSIVE LICENSING AGREEMENT WITH AETERNA ZENTARIS FOR THE FIRST AND ONLY ORALLY ADMINISTERED APPROVED MEDICINE FOR THE DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS
March 16, 2023Business Services
BASILDON, UK, 16 MARCH 2023 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the …
Zolgensma®▼ (onasemnogene abeparvovec) receives NICE final draft guidance in presymptomatic babies up to 12 months with spinal muscular atrophy (SMA)
March 16, 2023Business Services
London, UK, 16th March 2023 – Novartis Gene Therapies has confirmed that the National Institute for Health and Care Excellence …
Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology
March 16, 2023Business Services
Boston, Massachusetts, March 16th, 2023 – Aldena Therapeutics Inc. (Aldena) a private biotech company pioneering siRNA-based therapies for dermatological indications, …
DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine
March 15, 2023Business Services
Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that …
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023Business Services
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further …
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
March 14, 2023Business Services
AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the …
Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved
March 14, 2023Business Services
14 March 2023, Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
